Real-Life Experience of Continuously Infused Ceftolozane/Tazobactam in Patients with Bronchiectasis and Multidrug-Resistant <i>Pseudomonas aeruginosa</i> Infection in the Outpatient Setting

• Main Authors: Francesco Venuti (Author), Alberto Gaviraghi (Author), Amedeo De Nicolò (Author), Giacomo Stroffolini (Author), Bianca Maria Longo (Author), Alessia Di Vincenzo (Author), Fabio Antonino Ranzani (Author), Matilde Quaranta (Author), Francesca Romano (Author), Eleonora Catellani (Author), Carlotta Marchiaro (Author), Giacoma Cinnirella (Author), Antonio D'Avolio (Author), Stefano Bonora (Author), Andrea Calcagno (Author)
• Format: Book
• Published: MDPI AG, 2023-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

(1) Background: Ceftolozane/tazobactam (C/T) is a novel β-lactam/β-lactamase inhibitor with excellent activity against the multidrug-resistant (MDR) <i>P. aeruginosa</i>. Continuous infusion (CI) dosing allows the optimization of pharmacokinetic and pharmacodynamic (PK/PD) properties of...